Compounds > troxacitabine
Page last updated: 2024-09-03

troxacitabine and Myelodysplastic Syndromes

troxacitabine has been researched along with Myelodysplastic Syndromes in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alvarado, Y; Apostolidou, E; Bivins, C; Cortes, JE; Giles, FJ; Kantarjian, HM1
Estey, E; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S1
Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA1
Baker, SD; Beran, M; Bivins, C; Cortes, JE; Giles, FJ; Jolivet, J; Kantarjian, HM; O'Brien, S; Smith, TL; Thomas, DA1
Andreeff, M; Baker, SD; Bivins, C; Cortes, JE; Garcia-Manero, G; Giles, FJ; Jolivet, J; Kantarjian, HM; Miller, CB; O'Brien, SM; Thomas, DA1

Trials

5 trial(s) available for troxacitabine and Myelodysplastic Syndromes

ArticleYear
Troxacitabine activity in extramedullary myeloid leukemia.
    Hematology (Amsterdam, Netherlands), 2002, Volume: 7, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytosine; Dioxolanes; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome

2002
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
    Acta haematologica, 2002, Volume: 108, Issue:3

    Topics: Acute Disease; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cytosine; Dioxolanes; Female; Gemtuzumab; Hepatic Veno-Occlusive Disease; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Sialic Acid Binding Ig-like Lectin 3

2002
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome

2003
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-01, Volume: 19, Issue:3

    Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Blast Crisis; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma

2001
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Feb-01, Volume: 20, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction

2002